支气管扩张市场－全球及区域分析：按国家、地区划分－分析与预测（2025-2035）

全球支气管扩张市场分析与预测（2025-2035）

支气管扩张是一种慢性呼吸系统疾病，肺部的支气管（气道）会异常且不可逆地扩张。

气道扩张会导致黏液排放障碍、性行为感染和肺部发炎。这种情况可导致慢性咳嗽、黏液分泌过多和频繁的肺部感染疾病。支气管扩张可作为原发性疾病出现，也可继发于其他疾病，例如囊肿纤维化、慢性阻塞性肺病（COPD）和免疫力缺乏。它也可能由反覆呼吸道感染疾病、结核病或吸入异物引起。

支气管扩张症市场成长的驱动因素包括全球盛行率上升、公众意识增强、治疗方法进步以及人口老化导致呼吸系统疾病易感人群增加。慢性呼吸系统疾病，例如慢性阻塞性肺病（COPD）、囊肿纤维化和自体免疫疾病，常常导致支气管扩张症，使得需要有效治疗以控制症状和预防疾病进展的患者群体日益壮大。全球人口老化是支气管扩张症盛行率上升的主要原因。此外，人们逐渐认识到支气管扩张症是慢性呼吸症状的常见原因，这提高了诊断率，从而推动了对控制发炎、感染疾病和黏液分泌的治疗方法的需求。例如，COPD是支气管扩张症的主要危险因素，其盛行率的上升促使人们采用噻托溴铵（思力华）和Fluticasone等长期吸入疗法来控制气流阻塞并改善患者预后。

此外，近年来支气管扩张的治疗模式发生了显着变化，从症状治疗转向更有针对性的疾病修正治疗。大环内酯类抗生素（例如阿奇霉素）现在被常规用于减少病情加重、预防感染疾病和改善患者的生活品质。

此外，生物製药和免疫调节剂的研发为支气管扩张的治疗提供了新的可能性，尤其适用于合併自体免疫疾病或发炎性疾病的患者。这些治疗方法可针对特定的免疫通路，旨在减轻发炎并预防肺损伤。人们对生物製药（例如抗TNF-α製剂和白细胞介素抑制剂）的作用越来越感兴趣，这些药物有望彻底改变支气管扩张相关慢性发炎患者的治疗方式。

儘管治疗方法取得了进展，但挑战仍然存在。例如，生物製药和吸入疗法的高昂费用可能会限制患者获得治疗的机会，尤其是在低收入国家的医疗体系中。此外，由于支气管扩张是一种需要长期管理的慢性疾病，治疗的连续性仍然是一个重要问题。确保患者坚持处方治疗方案，尤其是在涉及复杂的吸入疗法和每日服用抗生素的情况下，仍然是有效治疗的一大障碍。

支气管扩张症作为一种独特的临床疾病的认知，正为更精准的医疗方法铺平道路。这一趋势的驱动力源于基因谱分析和生物标记发现技术的进步，这些技术使得针对特定患者特征的标靶治疗成为可能。特别是，针对囊肿纤维化相关性支气管扩张症和自体免疫支气管扩张症的个人化疗法有望获得市场认可。生物製药和免疫调节剂是个人化医疗中最有前景的治疗选择之一，它们针对参与气道发炎和损伤的特定路径。

本报告对全球支气管扩张市场进行了分析，并概述了市场状况、区域趋势以及参与该市场的公司的概况。

目录

执行摘要

第一章 全球支气管扩张市场：产业展望

• 市场概览
• 支气管扩张的区域流行病学分析
• 监管状态
• 主要趋势
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场约束
  • 市场机会

2. 全球支气管扩张市场（按地区划分，单位：百万美元），2023-2035年

• 北美洲
  • 市场动态
  • 市场规模及预测
• 欧洲
  • 市场动态
  • 市场规模及预测
• 亚太地区
  • 市场动态
  • 市场规模及预测

3. 全球支气管扩张市场－竞争格局与公司概况

• 关键策略和发展（按公司划分）
  • 资金筹措活动
  • 併购
  • 监管部门核准
  • 伙伴关係、合作与业务拓展
• 公司简介
  • Insmed Incorporated
  • AstraZeneca
  • ZAMBON COMPANY SPA
  • Chiesi Farmaceutici SpA
  • Armata Pharmaceuticals
  • Merck
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • 其他的

第四章调查方法

Global Bronchiectasis Market, Analysis and Forecast: 2025-2035

Bronchiectasis is a chronic respiratory condition characterized by the abnormal and irreversible dilation of the bronchial tubes (airways) in the lungs. This widening of the airways leads to impaired mucus clearance, recurrent infections, and inflammation of the lungs. The condition can result in chronic cough, excessive mucus production, and frequent lung infections. Bronchiectasis may arise as a primary disease or be secondary to other conditions such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), or immunodeficiency disorders. It can also result from recurrent respiratory infections, tuberculosis, or inhalation of foreign bodies.

The bronchiectasis market is driven by an increasing global prevalence of the condition, growing awareness, advancements in treatment modalities, and an aging population that is more susceptible to respiratory diseases. Chronic respiratory conditions like COPD, cystic fibrosis, and autoimmune disorders often lead to bronchiectasis, contributing to a growing patient base that requires effective treatments to manage symptoms and prevent disease progression. As the global population ages, the prevalence of bronchiectasis is rising. Moreover, the increasing recognition of bronchiectasis as a common cause of chronic respiratory symptoms is leading to higher diagnosis rates, fueling the demand for treatments that manage inflammation, infections, and mucus production. For instance, the increasing prevalence of COPD, a major risk factor for bronchiectasis, is driving the adoption of long-term inhaled therapies like tiotropium (Spiriva) and fluticasone to manage airflow obstruction and improve patient outcomes.

In addition, the treatment landscape for bronchiectasis has evolved significantly in recent years, shifting from symptomatic treatments to more targeted, disease-modifying therapies. Macrolide antibiotics (e.g., azithromycin) are now routinely used to reduce exacerbations, prevent infections, and improve quality of life for patients.

Also, the development of biologics and immunomodulators represents the next frontier for treating bronchiectasis, especially in patients with autoimmune or inflammatory conditions. These therapies aim to target specific immune system pathways, reducing inflammation and preventing lung damage. There is growing interest in the role of biologics such as anti-TNF-alpha agents and interleukin inhibitors, which could significantly change the management of patients with chronic inflammation in bronchiectasis.

Despite the advances in treatment, challenges remain, such as high costs associated with biologic therapies and inhaled treatments, which can limit access, particularly in lower-income healthcare systems. Additionally, treatment adherence remains a significant issue, as bronchiectasis is a chronic condition requiring long-term management. Ensuring that patients stick to prescribed regimens, especially when involving complex inhalation therapies or daily antibiotics, remains a barrier to effective treatment.

The growing recognition of bronchiectasis as a distinct clinical condition is opening the door to more precision medicine approaches. This trend is driven by advancements in genetic profiling and biomarker discovery, which allow for targeted treatments tailored to specific patient profiles. Personalized therapies, particularly those aimed at cystic fibrosis-related bronchiectasis and autoimmune-driven bronchiectasis, are expected to gain traction in the market. Biologics and immunomodulators are among the most promising treatment options in personalized medicine, targeting specific pathways involved in airway inflammation and damage.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Bronchiectasis Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis of Bronchiectasis, By Region
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Bronchiectasis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Bronchiectasis Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Bronchiectasis Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Bronchiectasis Market, by Country
      • 2.3.2.1.1 Japan

3. Global Bronchiectasis Market -Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development, by Company
  • 3.1.1 Funding Activities
  • 3.1.2 Mergers and Acquisitions
  • 3.1.3 Regulatory Approvals
  • 3.1.4 Partnerships, Collaborations and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Insmed Incorporated
    • 3.2.1.1 Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 AstraZeneca
    • 3.2.2.1 Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 ZAMBON COMPANY S.P.A.
    • 3.2.3.1 Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Chiesi Farmaceutici S.p.A
    • 3.2.4.1 Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 Armata Pharmaceuticals
    • 3.2.5.1 Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View
  • 3.2.6 Merck
    • 3.2.6.1 Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Sanofi
    • 3.2.7.1 Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers
    • 3.2.7.4 Key Personnel
    • 3.2.7.5 Analyst View
  • 3.2.8 Boehringer Ingelheim International GmbH
    • 3.2.8.1 Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers
    • 3.2.8.4 Key Personnel
    • 3.2.8.5 Analyst View
  • 3.2.9 Others

4. Research Methodology

List of Figures

• Figure: Bronchiectasis Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Bronchiectasis Market, 2024 and 2035
• Figure: Global Bronchiectasis Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Bronchiectasis Market, $Million, 2023-2035
• Figure: Europe Bronchiectasis Market, $Million, 2023-2035
• Figure: Asia-Pacific Bronchiectasis Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Bronchiectasis Market Dynamics, Impact Analysis
• Table: Global Bronchiectasis Market (by Region), $Million, 2023-2035